Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-022648

CHIEF SCIENTIFIC OFFICER sold 12,500 shares at an average $19.86 ($248,217)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2025-08-19 Sale : show line 1 in the form 10b5-1 −5,000 $19.62 $98,118 947,688 I
2025-08-21 Sale : show line 2 in the form 10b5-1 −7,500 $20.01 $150,099 940,188 I
Open-market sales · 12,500 sh · avg $19.86 · $248,217
Loading xslF345X05/form4-08212025_100834.xml…